BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35429302)

  • 21. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 22. Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma.
    Yin F; Shu L; Liu X; Li T; Peng T; Nan Y; Li S; Zeng X; Qiu X
    J Exp Clin Cancer Res; 2016 Aug; 35(1):127. PubMed ID: 27567667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of multiple databases identifies crucial genes correlated with prognosis of hepatocellular carcinoma.
    Lin Z; Huang X; Ji X; Tian N; Gan Y; Ke L
    Sci Rep; 2022 May; 12(1):9002. PubMed ID: 35637248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.
    Qin L
    Front Med; 2014 Mar; 8(1):24-32. PubMed ID: 24464486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma.
    Chimparlee N; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Payungporn S; Poovorawan Y; Tangkijvanich P
    Asian Pac J Cancer Prev; 2015; 16(16):7211-7. PubMed ID: 26514514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma.
    Deng Z; Wang J; Xu B; Jin Z; Wu G; Zeng J; Peng M; Guo Y; Wen Z
    Biomed Res Int; 2019; 2019():2408348. PubMed ID: 31828095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel biomarkers for hepatocellular carcinoma using transcriptome analysis.
    Xia Q; Li Z; Zheng J; Zhang X; Di Y; Ding J; Yu D; Yan L; Shen L; Yan D; Jia N; Chen W; Feng Y; Wang J
    J Cell Physiol; 2019 Apr; 234(4):4851-4863. PubMed ID: 30272824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.
    Zapf MA; Kothari AN; Weber CE; Arffa ML; Wai PY; Driver J; Gupta GN; Kuo PC; Mi Z
    Surgery; 2015 Oct; 158(4):1039-47; discussion 1047-8. PubMed ID: 26189955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma.
    Peng SY; Ou YH; Chen WJ; Li HY; Liu SH; Pan HW; Lai PL; Jeng YM; Chen DC; Hsu HC
    Int J Oncol; 2005 Apr; 26(4):1053-61. PubMed ID: 15754002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?
    Cabiati M; Gaggini M; De Simone P; Del Ry S
    Clin Exp Med; 2021 Nov; 21(4):555-562. PubMed ID: 33905035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying 13 Hub Genes Associated with Progression and Prognosis of Hepatocellular Carcinoma with Weighted Gene Co-Expression Network Analysis.
    Liu Y; Cheng R; Chang Q; Wu Y; Liu C; Liu Y; Wu X; Cheng L; Hu L; Yin J
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):59-69. PubMed ID: 34587436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma.
    Lu C; Fang S; Weng Q; Lv X; Meng M; Zhu J; Zheng L; Hu Y; Gao Y; Wu X; Mao J; Tang B; Zhao Z; Huang L; Ji J
    Cell Commun Signal; 2020 Jun; 18(1):97. PubMed ID: 32576292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.
    Long J; Chen P; Lin J; Bai Y; Yang X; Bian J; Lin Y; Wang D; Yang X; Zheng Y; Sang X; Zhao H
    Theranostics; 2019; 9(24):7251-7267. PubMed ID: 31695766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.
    Ren FH; Yang H; He RQ; Lu JN; Lin XG; Liang HW; Dang YW; Feng ZB; Chen G; Luo DZ
    BMC Cancer; 2018 Jan; 18(1):12. PubMed ID: 29298665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection.
    Beckebaum S; Chen X; Sotiropoulos GC; Radtke A; Daoudaki M; Baba HA; Wohlschlaeger J; Broelsch CE; Gerken G; Cicinnati VR
    Transplant Proc; 2008 Nov; 40(9):3182-4. PubMed ID: 19010227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value and underlying mechanism of KIAA0101 in hepatocellular carcinoma: database mining and co-expression analysis.
    Xu W; Wang X; Wu X; Yu S; Xiong J; Sang X; Zheng Y; Zhang Z
    Aging (Albany NY); 2020 Aug; 12(16):16420-16436. PubMed ID: 32855364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of osteopontin in hepatocellular carcinoma.
    Gotoh M; Sakamoto M; Kanetaka K; Chuuma M; Hirohashi S
    Pathol Int; 2002 Jan; 52(1):19-24. PubMed ID: 11940202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
    Zhan K; Bai Y; Liao S; Chen H; Kuang L; Luo Q; Lv L; Qiu L; Mei Z
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma.
    Zhang Y; Tang Y; Guo C; Li G
    Aging (Albany NY); 2021 May; 13(9):12865-12895. PubMed ID: 33946043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.
    Wu M; Jiang L
    Dig Dis Sci; 2022 Jan; 67(1):146-158. PubMed ID: 33495920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.